713 related articles for article (PubMed ID: 18232728)
21. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
22. Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Yener U; Avsar T; Akgün E; Şeker A; Bayri Y; Kılıç T
J Neurosurg; 2012 Oct; 117(4):697-704. PubMed ID: 22900848
[TBL] [Abstract][Full Text] [Related]
23. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
George D
Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
[TBL] [Abstract][Full Text] [Related]
24. Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells.
Lederle W; Stark HJ; Skobe M; Fusenig NE; Mueller MM
Am J Pathol; 2006 Nov; 169(5):1767-83. PubMed ID: 17071599
[TBL] [Abstract][Full Text] [Related]
25. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
28. Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor.
Rosenberg A; Mathew P
Expert Opin Investig Drugs; 2013 Jun; 22(6):787-94. PubMed ID: 23540855
[TBL] [Abstract][Full Text] [Related]
29. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.
Roussidis AE; Theocharis AD; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2007; 14(7):735-43. PubMed ID: 17346159
[TBL] [Abstract][Full Text] [Related]
30. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
[TBL] [Abstract][Full Text] [Related]
31. Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
Falcon BL; Pietras K; Chou J; Chen D; Sennino B; Hanahan D; McDonald DM
Am J Pathol; 2011 Jun; 178(6):2920-30. PubMed ID: 21641409
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology of imatinib (STI571).
Buchdunger E; O'Reilly T; Wood J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
[TBL] [Abstract][Full Text] [Related]
33. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.
Cristofanilli M; Morandi P; Krishnamurthy S; Reuben JM; Lee BN; Francis D; Booser DJ; Green MC; Arun BK; Pusztai L; Lopez A; Islam R; Valero V; Hortobagyi GN
Ann Oncol; 2008 Oct; 19(10):1713-9. PubMed ID: 18515258
[TBL] [Abstract][Full Text] [Related]
35. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
37. Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.
Semela D; Das A; Langer D; Kang N; Leof E; Shah V
Gastroenterology; 2008 Aug; 135(2):671-9. PubMed ID: 18570897
[TBL] [Abstract][Full Text] [Related]
38. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor.
Abouantoun TJ; MacDonald TJ
Mol Cancer Ther; 2009 May; 8(5):1137-47. PubMed ID: 19417143
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.
Calipel A; Landreville S; De La Fouchardière A; Mascarelli F; Rivoire M; Penel N; Mouriaux F
Clin Exp Metastasis; 2014 Jun; 31(5):553-64. PubMed ID: 24652072
[TBL] [Abstract][Full Text] [Related]
40. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
